Deal Watch: Anticipated Shire/Baxalta Merger Steals Attention From J.P. Morgan
Industry's leading deal-making stage shows continued focus on immuno-oncology, with activity by Merck, Novartis and AstraZeneca.
You may also be interested in...
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.